Barclays lowered the firm’s price target on Twist Bioscience (TWST) to $52 from $55 and keeps an Overweight rating on the shares. The company reported a solid quarter with a fiscal 2025 guide better than expectations despite a tough budgetary macro environment, the analyst tells investors in a research note. The firm sees the business as still on track to deliver 50% gross margins in Q4.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz
- Morning Movers: Liberty Energy, Tesla up after President-elect Trump alliance
- Twist Bioscience sees FY25 revenue $367M-$377M, consensus $373.17M
- Twist Bioscience reports Q4 EPS (59c), consensus (69c)
- Twist Bioscience sees Q1 revenue $87M, consensus $84.27M